IFRX.US InflaRx N.V.

Healthcare Biotechnology USA Stocks
1.17 USD
Close of Nov 15, 2026
0.7984 2.95
Market cap
USD 172M
P/E
-
P/B
1.08x
ROE
-17.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IFRX.US undervalued?

Graham number

The Graham number of InflaRx N.V. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InflaRx N.V. fundamental analysis

No fundamental analysis for InflaRx N.V. yet.

InflaRx N.V. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfun…

Full company profile